CMPX Stock Analysis: Compass Therapeutics | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 409m USD | 12M Return: -12.1% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 6.57M
Qual. Beats: 0
Qual. Beats: 1
Warnings
Tailwinds
No distinct edge detected
Seasonality 5.3 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Compass Therapeutics is a clinical-stage biopharmaceutical company headquartered in Boston, Massachusetts, focused on developing antibody-based therapeutics primarily for oncology. Its lead candidate, tovecimig, is a bispecific antibody that simultaneously targets DLL4 and VEGF-A, two pathways involved in tumor angiogenesis. The pipeline also includes CTX-471, a CD137 agonist monoclonal antibody, and two additional bispecific candidates-CTX-8371 (PD-1/PD-L1) and CTX-10726 (PD-1/VEGF-A)-highlighting a strategic emphasis on dual-targeting immuno-oncology approaches. Founded in 2014 and listed on NASDAQ since 2021, Compass operates within the biotechnology sub-sector, where clinical-stage companies typically rely on capital markets and partnership funding to advance drug candidates through early-stage trials before generating any product revenue.
- Tovecimig Phase 1/2 data readout approaches in solid tumors
- Bispecific pipeline competes in crowded PD-1 checkpoint inhibitor market
- Cash runway and capital allocation critical amid clinical development burn
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.26 > 0.02 and ΔFCF/TA 7.68 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.26 > 3% & CFO -53.2m > Net Income -68.2m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 19.04 > 1.5 & < 3 |
| Outstanding Shares: last quarter (186.4m) vs 12m ago 34.84% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.65%; Δ -0.65% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.90 (Total Current Assets 195.7m - Total Current Liabilities 10.3m) / Total Assets 205.2m |
| B: -2.19 (Retained Earnings -449.5m / Total Assets 205.2m) |
| C: -0.41 (EBIT TTM -68.2m / Avg Total Assets 168.3m) |
| D: 9.97 (Book Value of Equity 186.5m / Total Liabilities 18.7m) |
| Altman-Z'' = 6.54 = AAA |
As of July 08, 2026, the stock is trading at USD 2.32 with a total of 3,212,552 shares traded. Over the past week, the price has changed by +7.41%, over one month by +14.85%, over three months by -56.31% and over the past year by -12.12%.
Current recommended Stop Loss: 2.10 (which is 9.5% or 1.6 ATR below the current price).
Compass Therapeutics has received a consensus analysts rating of 4.78. Therefore, it is recommended to buy CMPX.
- StrongBuy: 7
- Buy: 2
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 8.5 | 266.4% |
P/S = 269.2826
P/B = 2.0957
Revenue TTM = 0.0 USD
EBIT TTM = -68.2m USD
EBITDA TTM = -67.0m USD
Long Term Debt = 8.42m USD (estimated: total debt 9.79m - short term 1.37m)
Short Term Debt = 1.37m USD (from shortTermDebt, last quarter)
Debt = 9.79m USD (from shortLongTermDebtTotal, last quarter) (leases 9.79m already included)
Net Debt = -184.9m USD (calculated: Debt 9.79m - CCE 194.7m)
Enterprise Value = 223.9m USD (408.8m + Debt 9.79m - CCE 194.7m)
Interest Coverage Ratio = unknown (Ebit TTM -68.2m / Interest Expense TTM 0.0)
EV/FCF = -4.20x (Enterprise Value 223.9m / FCF TTM -53.3m)
FCF Yield = -23.80% (FCF TTM -53.3m / Enterprise Value 223.9m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 1.47m) / Revenue TTM)
Tobins Q-Ratio = 1.09 (Enterprise Value 223.9m / Total Assets 205.2m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 9.79m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -53.9m (EBIT -68.2m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 19.04 (Total Current Assets 195.7m / Total Current Liabilities 10.3m)
Debt / Equity = 0.05 (Debt 9.79m / totalStockholderEquity, last quarter 186.5m)
Debt / EBITDA = 2.76 (negative EBITDA) (Net Debt -184.9m / EBITDA -67.0m)
Debt / FCF = 3.47 (negative FCF - burning cash) (Net Debt -184.9m / FCF TTM -53.3m)
Total Stockholder Equity = 171.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -40.50% (Net Income -68.2m / Total Assets 205.2m)
RoE = -39.75% (Net Income TTM -68.2m / Total Stockholder Equity 171.5m)
RoCE = -37.89% (EBIT -68.2m / Capital Employed (Equity 171.5m + L.T.Debt 8.42m))
RoIC = -27.44% (negative operating profit) (NOPAT -53.9m / Invested Capital 196.3m)
WACC = 12.36% (E(408.8m)/V(418.6m) * Re(12.66%) + D(9.79m)/V(418.6m) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 12.66% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 88.66 | Cagr: 18.32%
[DCF] Fair Price = unknown (Cash Flow -53.3m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.06 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 2.15 | # QB: 1
EPS current Quarter (2026-06-30): EPS=-0.11 | Chg30d=+0.73% | Revisions=-50% | Analysts=12
EPS next Quarter (2026-09-30): EPS=-0.11 | Chg30d=+0.56% | Revisions=-40% | Analysts=12
EPS current Year (2026-12-31): EPS=-0.43 | Chg30d=+0.50% | Revisions=-17% | GrowthEPS=-3.4% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-0.46 | Chg30d=-0.54% | Revisions=-67% | GrowthEPS=-6.5% | GrowthRev=+1328.3%
[Analyst] Revisions Ratio: -71% (up=1, down=13)